[Short-term and median-term effects of tienilic acid in hypertension]. 1979

R Pirani, and A M Tomasi, and P Gruppillo, and A Masoni

Fifty nine patients suffering from slight or moderate essential arterial hypertension underwent hypotensive treatment. After one week of wash-out, therapeutic administration of tienilic acid in doses of 500 mg per day was begun; in the third week we combined a non diuretic hypotensive drug (prazosin, propranolol, alfametil-dopa). At the beginning of the study all patients underwent an ECG, a clinical cardiological examiniation, funduscopy examination, funduscopy examination, a heart X - ray in 3 standard positions and a routine blood test which was repeated during and at the end of the treatment. The patients' blood pressure taken in an upright and supine position, showed statistically significant reductions for both systolic and diastolic values in all 3 groups, whereas the routine blood tests gave evidence of a marked reduction in the uriacid, triglycerides and potassium levels. In order to correct the latter we had to administer high oral doses of potassium, and in one case admittance to hospital was necessary since the potassium level was lower then 2.5 mEq/l.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008750 Methyldopa An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. Methyldopate,alpha-Methyldopa,Aldomet,Alphamethyldopa,Apo-Methyldopa,Dopamet,Dopegit,Dopegyt,Dopergit,Hydopa,Meldopa,Nu-Medopa,Sembrina,alpha-Methyl-L-Dopa,Apo Methyldopa,Nu Medopa,alpha Methyl L Dopa,alpha Methyldopa
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D011224 Prazosin A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION. Furazosin,Minipress,Pratsiol,Prazosin HCL,Prazosin Hydrochloride,HCL, Prazosin,Hydrochloride, Prazosin
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females

Related Publications

R Pirani, and A M Tomasi, and P Gruppillo, and A Masoni
January 1981, Acta medica Scandinavica. Supplementum,
R Pirani, and A M Tomasi, and P Gruppillo, and A Masoni
January 1979, Postgraduate medical journal,
R Pirani, and A M Tomasi, and P Gruppillo, and A Masoni
January 1979, Postgraduate medical journal,
R Pirani, and A M Tomasi, and P Gruppillo, and A Masoni
January 1979, Postgraduate medical journal,
R Pirani, and A M Tomasi, and P Gruppillo, and A Masoni
January 1981, Minerva nefrologica,
R Pirani, and A M Tomasi, and P Gruppillo, and A Masoni
January 1979, Postgraduate medical journal,
R Pirani, and A M Tomasi, and P Gruppillo, and A Masoni
January 1980, Advances in experimental medicine and biology,
R Pirani, and A M Tomasi, and P Gruppillo, and A Masoni
January 1979, Postgraduate medical journal,
R Pirani, and A M Tomasi, and P Gruppillo, and A Masoni
January 1979, Postgraduate medical journal,
R Pirani, and A M Tomasi, and P Gruppillo, and A Masoni
August 1980, Annals of the rheumatic diseases,
Copied contents to your clipboard!